Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · MIMEDX GROUP, INC. (MDXG)

MIMEDX Q3 net sales fall 45% to $62 million; company posts $9 million net loss

Negative Impact 4 of 5 earnings Written later

MIMEDX reported third-quarter 2026 net sales of $62 million, down 45% from $114 million a year earlier, and a net loss of $9 million compared with net income of $17 million in the prior-year quarter. Wound sales fell 71% year over year, while Surgical sales rose 9%, and the company now expects 2026 net sales of $250 million to $260 million. The results and the pending Sanara MedTech acquisition, which still awaits FTC review, bear directly on shareholder value.

Key points

  • Q3 2026 net sales were $62 million versus $114 million a year earlier; diluted loss per share was $0.06 versus earnings of $0.11.
  • Adjusted EBITDA was $2 million in the quarter, compared with $35 million in the third quarter of 2025.
  • The company now expects 2026 net sales of $250 million to $260 million and fourth-quarter Adjusted EBITDA above the third quarter.
  • A patent license agreement with a wound care competitor provides $25 million payable in five $5 million installments, with the first already received.

The filing

CompanyMIMEDX GROUP, INC. (MDXG)
Form8-K, current report
Filed with the SECOct 28, 2026, 4:03 PM ET
Accession number0001376339-26-000094

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.